News
This page is intended for media, analysts, and investors.
Read the latest Mereo BioPharma news
Together with patient communities, healthcare professionals, commercial partners and with the support of investors, we are constantly making progress on our mission. We are committed to regularly updating our investors, analysts, and the media on this progress. Here you can read the latest Mereo news and learn about events at which we are speaking.
If you would like to get in touch, you will find ways to contact us on this page.
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
London, November 10, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2025, and provided recent corporate highlights.
Mereo to Participate in Fireside Chat at the Jefferies Healthcare Conference in London
London, November 13, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in London on Monday, November 17, 2025, at 10:00 am ET / 3:00 pm GMT.
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.
Mereo BioPharma Group plc announces that the merger with OncoMed Pharmaceuticals, Inc. ("OncoMed" NASDAQ:OMED) announced on 5 December 2018 has today completed.
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting
LONDON, April 18, 2019 -- Mereo BioPharma Group plc, announces today that stockholders of OncoMed (NASDAQ: OMED) have approved the transactions contemplated by the merger agreement dated 5 December 2018 between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo (the "Merger"), at a meeting of OncoMed's stockholders duly convened and held on 17 April 2019.
Mereo Publicly Files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
Mereo BioPharma Group plc a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that a further step towards the proposed combination (the "Proposed Transaction") with OncoMed Pharmaceuticals, Inc. ("OncoMed") has been taken, with the filing by Mereo of its preliminary registration statement on Form F-4 (the "Form F-4") with the U.S. Securities and Exchange Commission (the "SEC").
Mereo Biopharma Announces Positive Results From The Safety Extension Study To The Phase 2b Clinical Trial Of Bgs-649 For The Treatment Of Hypogonadotropic Hypogonadism In Obese Men
Mereo BioPharma : first patient dosed in phase 2 alpha-1 antitrypsin deficiency study
Mereo announces positive top-line results from Phase 2 trial with BCT-197 (acumapimod)
Mereo BioPharma Group plc (AIM: MPH), a multi-asset biopharmaceutical company focused on the acquisition, development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, today announces positive top-line data from a Phase 2 clinical trial with BCT-197 (acumapimod), a novel, orally active p38 MAP kinase inhibitor in development as a first-line therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Mereo receives EMA PRIME designation for BPS-804 to treat osteogenesis imperfecta
Mereo BioPharma Group plc (AIM: MPH), a multi-asset, clinical stage, biopharmaceutical company focused on rare and specialty diseases, today announces that the European Medicines Agency (EMA) has granted BPS-804 PRIority MEdicines (PRIME) designation for the treatment of osteogenesis imperfecta (OI), or “brittle bone disease
Mereo BioPharma announces agreement with AstraZeneca AB (“AstraZeneca”) for an exclusive license and option to acquire AZD9668
Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, today announces that it has reached an agreement with AstraZeneca for an exclusive license, including an option to acquire, AZD9668, an oral inhibitor of neutrophil elastase
